Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1 –Infected Women with High CD4 Cell Count (IMPAACT PROMISE): A randomized, Open-Label, Clinical Trial

Overview

This randomized trial aimed to compare the efficacy of prolonged infant nevirapine (iNVP) prophylaxis versus maternal antiretroviral therapy (mART) for prevention of mother-to-child HIV transmission through breastfeeding cessation. After the randomized open-label trial concluded that both mART and iNVP prophylaxis strategies were safe and associated with very low breastfeeding HIV-1 transmission and high infant HIV-1-free survival at 24 months.